Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorambucil
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Chlorambucil is an oral chemotherapy drug classified as an alkylating agent and a derivative of nitrogen mustard. It is primarily used to treat chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma. The drug works by alkylating and cross-linking DNA, thereby interfering with DNA replication, RNA transcription, and protein synthesis in cancer cells. This leads to cell cycle arrest and apoptosis through mechanisms involving p53 accumulation and activation of pro-apoptotic proteins such as Bax. Chlorambucil also exhibits immunosuppressive activity by suppressing lymphocytes. It was originally developed by Glaxo (now part of GSK).
- Brand names
- Leukeran
- Other names
- ChlorambucilumChloraminopheneChlorbutinum
02
Targets
DNAGSTA1 (Glutathione S-transferase A1)
Beyond the preview
Go deeper on chlorambucil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorambucil.